Anti-Mouse CD16.2 (9E9) In Vivo Antibody- Low Endotoxin

Product Specifications

Background

According to surface plasmon resonance, 9E9 has strong reactivity to FcγRIV as well as low level binding to FcγRII and FcγRIII. In vivo, 9E9 binds and blocks FcγRIII only when 9E9 first binds FcγRIV on the same effector cell, resulting in concurrent inhibition of FcγRIII and FcγRIV. Native 9E9 binds to FcγRII and FcγRIII via the Fc. Blocking studies with 9E9 show that FcγRIV is necessary for IgG2a and IgG2b mediated platelet clearance in vivo. Additionally, blocking FcγRIV with 9E9 reduces B-cell depletion. 9E9 also interferes with immune complex binding to FcγRIV and can block FcγRIII on macrophages and neutrophils.

CAS Number

9007-83-4

Specifications

9E9 activity is primarily directed against mouse CD16.2 / FcγRIV but can also bind and block FcγRIII in vivo.

Product Name Alternative

FcγRIV

Host

Armenian Hamster

Species Reactivity

Mouse

Target

CD16.2

Isotype

IgG

Clone

9E9

Applications

Blocking, Flow Cytometry

Purification Method

This monoclonal antibody was purified using Protein A

Concentration

≥ 2.0 mg/mL

Endotoxin

<1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE

Buffer

ICH3001-100mL ICH3002-100mL ICH3003-100mL

Shipping Conditions

Blue ice

Storage Conditions

This antibody is stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Antigen Distribution

FcγRIV is expressed on the cell membrane of splenic and bone marrow dendritic cells, monocytes, and macrophages as well as peripheral blood monocytes, neutrophils, thioglycollate-elicited macrophages, and myeloid cells. FcγRIV is absent from lymphoid populations, T cells, B cells, NK cells, and other granulocytes.